Reverse Merger With Protara and Recapitalization (Details Textual)		3 Months Ended	12 Months Ended
	Jan. 09, 2020 shares	Mar. 31, 2020 USD ($) shares	Dec. 31, 2019 shares	Mar. 31, 2019 shares	Dec. 31, 2018 shares
Reverse Merger with Artara and Recapitalization (Textual)
Reverse stock split	1-for-40	On January 9, 2020, in connection with, and prior to the completion of, the Merger, Protara Therapeutics, Inc. effected a 1-for-40 reverse stock split of its common stock, or the Reverse Stock Split, Private ArTara changed its name from "ArTara Therapeutics, Inc."
Outstanding reverse stock	557,631
Common shares exchange ratio	0.190756
Shares available for issuance	2,627,533
Fair value of net assets | $		$ 34,532,627
Description of ownership rights		Immediately after the consummation of the Merger and prior to the consummation of the Private Placement, the former stockholders and option holders of Private ArTara owned, or held rights to acquire, approximately 75.2% of the fully-diluted Common Stock of Protara, with Protara Therapeutics, Inc.'s stockholders and option holders immediately prior to the Merger owning approximately 24.8% of the fully-diluted Common Stock of Protara.
Pre merger shares		557,631
Common Stock
Reverse Merger with Artara and Recapitalization (Textual)
Outstanding reverse stock		5,843,203	2,627,533	2,558,419	2,558,419
Common shares exchange ratio			0.190756
Reverse business combination (in shares)		1,033,907
Merger Agreement [Member]
Reverse Merger with Artara and Recapitalization (Textual)
Common shares exchange ratio	0.190756
Series A Convertible Preferred Stock [Member]
Reverse Merger with Artara and Recapitalization (Textual)
Convertible preferred stock		476,276
Private Placement [Member]
Reverse Merger with Artara and Recapitalization (Textual)
Subscription agreement, description		(i) 3,879.356 of shares of Protara Therapeutics, Inc.'s Series 1 Convertible Non-Voting Preferred Stock at a purchase price of approximately $7,011.47 per share for gross proceeds of $27,199,988 and proceeds, net of issuance costs, of $25,318,706, (ii) 1,896,888 shares of Protara Therapeutics, Inc.'s Common Stock at a purchase price of approximately $7.01 per share for gross proceeds of $13,299,974 and proceeds, net of issuance costs, of $12,413,337 and (B) Private ArTara issued in a private placement immediately prior to the Merger (the "ArTara Private Placement") 284,875 shares of Private ArTara common stock (post-Exchange Ratio basis) at a purchase price of approximately $7.01 per share (post-Exchange Ratio basis) (together with the Proteon Private Placement, the "Private Placements") for gross proceeds of $1,999,999 and proceeds, net of issuance costs, of $1,867,580. The shares issued in the Proteon Private Placement were registered for resale on a registration statement on Form S-3 filed and declared effective by the U.S. Securities and Exchange Commission (the "SEC") on January 30, 2020.
Converted Shares issued		18,954
2017 Equity Incentive Plan [Member]
Reverse Merger with Artara and Recapitalization (Textual)
Common shares exchange ratio	0.190756
Shares available for issuance	219,699
2014 Equity Incentive Plan [Member]
Reverse Merger with Artara and Recapitalization (Textual)
Shares available for issuance			1,048,300